Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Pier Luigi Zinzani, MD, PhD

Institute of Hematology “Seràgnoli” University of Bologna, Italy

N/A

Poster(s):

3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)